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prednisolone], ara-C [cytarabine],
and platinum) and NOPP (Novanrrone,
Oncovin, procarbazine, and pred
nisone). Both ATI and the extensive
irradiation, which is called central
lymphatic irradiation, Dr. Cox said,
have accomplished what standard
chemotherapy and radiation therapy
could not.
'We're very impressed that they're
both so effective,'' Cox said. "Both
of these approaches are more effec
tive than more modest treatment
approaches."
Although the radiation treatment
used is extensive, it falls short of
total-body irradiation (TBI), a fact
that Cox finds encouraging, given
the positive molecular responses he
has seen. Avoiding TBI is important
in order to preserve more intensive
therapy for subsequent treatment if
it is necessary.
"The long-term results of central
lymphatic irradiation," he said, "have
been encouraging." •

contact D,:
Cabanillas at (713) 792-2860, Dr.
Khouri at (713) 794-5743, or D1: Cox
at (713) 792-3411, or call the M. D.
Anderson Information Line at (800)
392-1611 or(713) 792-6161.
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---- PROTOCOLS-- -( Continued from page 3)
• Randomized comparison of alternating
triple therapy (ATT) versus CHOP in
patients with intermediate grade
lymphomas and immunoblastic lympho
mas with international index 2-5
(DM94-017). Physician: Fernando

Cabanillas, M.D.

Previously untreated patients who
have diffuse large cell, follicular large
noncleaved-cell, diffuse mixed, or
immunoblastic lymphoma (both T cell
and B cell) are eligible for this study.
They must be 16 years or older, have
an international index of 2-5, and have
no history of chronic obstructive or
restrictive lung disease or antecedent
malignancy with poor prognosis (<90%
probability of five-year survival). They
may have brain involvement but no
primary brain lymphoma.
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• Systemic vs. local therapy tor stage 1-111
low-grade lymphomas monitored by
polymerase chain reaction technique
(DM92-102). Physician: Fernando

Cabanillas, M.O.

This protocol, described in the
columns above, is for previously
untreated patients with follicular low
grade lymphoma or small cell lympho
cytic lymphoma, irrespective of bcl-2
status. Disease must be clinical stage 1111. Patients must be <76 years old, with
no divergent histology (e.g., intermedi
ate grade in one site and low grade in
another), no history of chronic obstruc·
tive or restrictive lung disease, and no
antecedent malignancy with poor
prognosis.
• A randomized phase Ill study of melato
nin plus CHOP for patients with large cell

lymphoma, tumor score <3 (DM98-009).

Physician: Maria Atma Rodriguez, M.D.

Patients with large cell lymphoma
(except forT-cell phenotype) who are
previously untreated and have a tumor
risk score of <3 are eligible. Patients
must have adequate marrow reserve
(ANG, >1 OOO/mm3 ; platelets, >100,000/
mm3), unless tymphoma is cause of low
counts. Serum creatinine and bilirubin
must each be <2 mg/dl.

about these clinical
trials, physicians or patients should call
the M. D. Anderson lr,Jonnation Line.
Those in the Un:ile<l States, call (800)
392-1611; those in llouston or outsiae
the United States, call (713) 792-6161.
Visit the M. D. Anderson Cancer Center
clinical trials Web site at http://
www. clinicaltrials.org.
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Careful Inspection, Early Detection
Important in Controlling Oral Cancer
by David Babaian and Beth W. Allen

'hile recognizing
the potential
gains from
prevention
studies under way and the
curative ability of surgery,
Associate Professor of Head
and Neck Surgery Gary L.
Clayman, D.D.S., M.D.,
emphasizes that early detection
remains the key to controlling
oral cancer.

•·without guestion, early diagnosis
is our greatest tool," Dr. Clayman said
in a recent interview. "Dentists and
primary care physicians are the
greatest health care screening pro
viders for oral cancer. Their recogni
tion of this process is critical." The
oral cavity extends from the lips to
the soft palate and includes the oral
tongue as well as the inside portions
of the cheeks and dental arches.
To promote prevention, M. D.
Anderson initiated clinical trials that
have now progressed into national
multi-instituional studies headed by
Waun K Hong, M.D., chai1man of
the Department of Thoracic and
Head and Neck Medical Oncology.
Dr. Clayman, who is deputy chair
man of the Department of Head and
Neck Surgery, said about one-half of
patients with oral cancer have ad
vanced disease at diagnosis, which
narrows their probability of living
five years or more to less than 50%.
Often symptomatic well before
they consult a physician, these pa
tients may postpone seeking treat
ment, often attributing pain to dental
or ear ailments. Dr. Clayman said
physicians sometimes fail to suspect
referred otalgia. Consultation may
even be postponed until such other
signs as leukoplak.ia, a precancerous
condition, ulcerations, or a neck
mass are visible.
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Inspection by an otolaryngologist,
who will perform a complete head
and neck examination, should yield
identification of the cancer and
detect other abnormalities along the
aerodigestive tract, Dr Clayman said.
Surgical treatment is often cura
tive for stage I or II disease, accord
ing to Dr. Clayman, who stressed
how organ and function preservation
were foremost considerations in
planning treatment. "Freguently
surgery can be used in early stage
disease as a single and curative
approach," he said. Patients can
avoid long-term adverse effects of
radiation therapy, he said, "and still
benefit from good functional and
cosmetic outcomes, which have an
impact on their quality of life-a
major issue." Oral cancer at a late
stage can have a long-term effect on
appearance and the ability to speak
or swallow.
Reserving other interventions,
in particular radiation therapy,
increases treatment options in
case of recurrence, metastasis,
or second primary malignancies.
"We certainly bdieve in
Anderson's multidisciplinary
approaches to all cancers, but
we also believe that if a single
modality of treatment can be
as effective as multiple modali
ties, then we prefer to treat
with a single modality if it
will benefit the patient in
both the short and the long
term," Dr. Clayman said.
To provide comprehensive
care, the M. D. Anderson
Head and 1 eek Center
coordinates professionals
from many disciplines,
including surgeons, medical
oncologists, and radiotherapist
whose practice is devoted to
,--head and neck cancers; speech
pathologists; specialized nurses;
and nutrition specialists. "It is
reaUy a team approach so that
we are all working together
rather than in 20 individual

directions," Dr. Clayman said. "The
M. D. Anderson head and neck
oncology program was one of the
very first to use the multidisciplinary
approach to the cancer patient."
"Because it is a very large referral
center for all bead and neck cancers,
we have a tremendous breadth of
experience," he said, adding that the
staff's focus also increases the depth
of knowledge.
The American Cancer Society
estimates that 30,300 new cases of
oral cancer will be diagnosed in 1998
in the United States, and men are
more than twice as likely to develop
oral cancer than are women. Though
80%-85% of patients with oral
cancer have a history of tobacco use
and most are older than 40 years of
age, Dr. Clayman says the incidence
of oral cancer appears to be rising
in the young and in the aged.
"We're seeing cases in much
younger patients. There appears
to be an evolution, an increasing
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